Welcome to the IKCEST

PLoS Pathogens | Vol.13, Issue.10 | | Pages

PLoS Pathogens

Pegivirus avoids immune recognition but does not attenuate acute-phase disease in a macaque model of HIV infection.

Adam L Bailey,Connor R Buechler,Daniel R Matson,Eric J Peterson,Kevin G Brunner,Mariel S Mohns,Meghan Breitbach,Laurel M Stewart,Adam J Ericsen,Christina M Newman,Michelle R Koenig,Emma Mohr,John Tan,Saverio Capuano,Heather A Simmons,David T Yang,David H O'Connor  
Abstract

Human pegivirus (HPgV) protects HIV+ people from HIV-associated disease, but the mechanism of this protective effect remains poorly understood. We sequentially infected cynomolgus macaques with simian pegivirus (SPgV) and simian immunodeficiency virus (SIV) to model HIV+HPgV co-infection. SPgV had no effect on acute-phase SIV pathogenesis-as measured by SIV viral load, CD4+ T cell destruction, immune activation, or adaptive immune responses-suggesting that HPgV's protective effect is exerted primarily during the chronic phase of HIV infection. We also examined the immune response to SPgV in unprecedented detail, and found that this virus elicits virtually no activation of the immune system despite persistently high titers in the blood over long periods of time. Overall, this study expands our understanding of the pegiviruses-an understudied group of viruses with a high prevalence in the global human population-and suggests that the protective effect observed in HIV+HPgV co-infected people occurs primarily during the chronic phase of HIV infection.

Original Text (This is the original text for your reference.)

Pegivirus avoids immune recognition but does not attenuate acute-phase disease in a macaque model of HIV infection.

Human pegivirus (HPgV) protects HIV+ people from HIV-associated disease, but the mechanism of this protective effect remains poorly understood. We sequentially infected cynomolgus macaques with simian pegivirus (SPgV) and simian immunodeficiency virus (SIV) to model HIV+HPgV co-infection. SPgV had no effect on acute-phase SIV pathogenesis-as measured by SIV viral load, CD4+ T cell destruction, immune activation, or adaptive immune responses-suggesting that HPgV's protective effect is exerted primarily during the chronic phase of HIV infection. We also examined the immune response to SPgV in unprecedented detail, and found that this virus elicits virtually no activation of the immune system despite persistently high titers in the blood over long periods of time. Overall, this study expands our understanding of the pegiviruses-an understudied group of viruses with a high prevalence in the global human population-and suggests that the protective effect observed in HIV+HPgV co-infected people occurs primarily during the chronic phase of HIV infection.

+More

Cite this article
APA

APA

MLA

Chicago

Adam L Bailey,Connor R Buechler,Daniel R Matson,Eric J Peterson,Kevin G Brunner,Mariel S Mohns,Meghan Breitbach,Laurel M Stewart,Adam J Ericsen,Christina M Newman,Michelle R Koenig,Emma Mohr,John Tan,Saverio Capuano,Heather A Simmons,David T Yang,David H O'Connor,.Pegivirus avoids immune recognition but does not attenuate acute-phase disease in a macaque model of HIV infection.. 13 (10),.

References

Disclaimer: The translated content is provided by third-party translation service providers, and IKCEST shall not assume any responsibility for the accuracy and legality of the content.
Translate engine
Article's language
English
中文
Pусск
Français
Español
العربية
Português
Kikongo
Dutch
kiswahili
هَوُسَ
IsiZulu
Action
Recommended articles

Report

Select your report category*



Reason*



By pressing send, your feedback will be used to improve IKCEST. Your privacy will be protected.

Submit
Cancel